Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide in Type 2 Diabetes and Obesity
NCT06037252Phase 2Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2023
- Primary completion
- Jan 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
A Phase 2 trial of tirzepatide in type 2 diabetes mellitus (T2DM), obesity, sponsored by Eli Lilly and Company. Started Sep 2023; status: active, not recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT06037252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06037252.